ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
Adia Nutrition (OTCQB: ADIA) announced that the SEC notified the company its Form 10 will not be subject to further review and will automatically become effective on February 3, 2026 (60 days after the Dec 5, 2025 filing). Upon effectiveness, Adia will transition to full SEC reporting under the Securities Exchange Act of 1934 and begin filing audited annual reports on Form 10-K and quarterly reports on Form 10-Q. The company said this status enhances transparency for investors and supports its plans to scale stem cell therapies, expand clinics and labs, and advance clinical studies. Effectiveness does not guarantee immediate listing on a national exchange but positions Adia to pursue eligibility requirements.
Adia Nutrition (OTCQB: ADIA) announced that Emmanuela Derisbrun, APRN, FNP-C, has moved from subcontractor to employed provider at Adia Med to support rising patient volume and the launch of an IRB-approved autism spectrum disorder regenerative study (NCT07304440). Emmanuela has administered stem cell treatments and therapeutic plasma exchange (TPE) at Adia Med and brings experience in IV vitamin therapies, hormone replacement, thyroid disorders, hypertension, diabetes, sickle cell disease, post-COVID care, and chronic pain management. The company said the hire strengthens clinical capacity as patient demand grows and the autism study begins; contact and study details are provided on ClinicalTrials.gov and Adia Med's website.
Adia Nutrition (OTCQB: ADIA) subsidiary Adia Med of Winter Park has begun recruiting for a 24-month randomized interventional study (NCT07304440) testing AdiaVita—an umbilical cord blood-derived stem cell and exosome product—combined with glutathione versus glutathione alone in ~100 children ages 3–12 with confirmed autism spectrum disorder. Primary outcome is change in total ATEC score at six months; safety, tolerability and quality of life will be tracked. The initial three-month phase includes a crossover option and participation requires a one-time fee of $12,000.
ADIA Nutrition (OTCQB: ADIA) announced the appointment of Dawn Bell as Chief Revenue Officer at its ADIA Labs subsidiary on January 8, 2026. Bell brings more than 15 years of sales strategy experience in medical device and pharmaceutical sectors and will lead revenue growth efforts and physician/clinic partnerships to integrate ADIA's regenerative therapies and diagnostic services.
The appointment coincides with ADIA's nationwide clinic expansion momentum and the planned launch of its first IRB-approved clinical study on autism at Adia Med of Winter Park, reflecting a push to advance clinical and commercial initiatives.
Adia Nutrition (OTCQB: ADIA) announced a patent-pending, randomized interventional clinical study for Autism Spectrum Disorder (NCT07304440) is now live on ClinicalTrials.gov. The trial plans to enroll approximately 100 children aged 3–12, comparing intravenous glutathione combined with umbilical cord blood-derived stem cells and exosomes (AdiaVita) versus glutathione alone.
Primary outcomes use ATEC scores to assess speech, sociability, sensory awareness, and behavior; the study includes a 24-month follow-up. Recruitment is expected to begin in January 2026 after independent IRB approval in December 2025.
Adia Nutrition (OTCQB: ADIA) recapped 2025 operational and financial milestones that management says position the company for scalable growth and a Nasdaq uplisting pathway.
Key disclosed achievements include revenue surges >200% quarter-over-quarter in preliminary Q3 results, profit margins exceeding 20%, a tripled sales force with four regional divisions, preferred-vendor access to over 4,000 personal injury physicians, divestiture of a non-core coffee subsidiary while retaining an 18% equity stake, advanced payer negotiations, and filing a Form 10 with expected approval in early 2026.
Adia Labs (OTCQB: ADIA) announced a strategic marketing partnership with BoldMD on December 17, 2025 to accelerate nationwide rollout of chiropractor-hosted pop-up longevity clinics.
The program builds on Adia Labs' alliance with Axia MD to provide physician oversight across all 50 states and aims to enable chiropractic practices to offer Adia's umbilical cord blood-derived stem cell products. BoldMD will supply targeted patient acquisition, brand development, and AI-powered CRM tools to support clinic scaling. The model targets >70,000 licensed chiropractors and cites a projected ~10% decade growth for the profession as a source pool for licensed clinic partners.
Adia Nutrition (OTCQB: ADIA) announced that independent IRB BeyondBound approved its patent-pending clinical study protocol for an Autism Spectrum Disorder (ASD) trial run by Adia Med of Winter Park LLC.
The randomized study will enroll 100 children ages 3–12 to compare combined glutathione plus umbilical cord blood-derived stem cells versus glutathione alone. Key outcomes include social interaction, communication, behavior, and quality of life.
Patient recruitment is expected to begin in January 2026. Study details have been submitted to ClinicalTrials.gov and are in final review before public posting.
Adia Nutrition (OTCQB: ADIA) filed a Form 10 registration statement with the U.S. Securities and Exchange Commission on December 8, 2025, prepared with assistance from the company's CFO, auditing accountant, corporate accountant, and legal counsel.
The filing is a strategic step toward full reporting status; once the Form 10 becomes effective (expected ~60 days after submission), Adia will begin reporting under the Securities Exchange Act of 1934 with audited financials and regular annual and quarterly disclosures. The company said Form 10 does not guarantee immediate national exchange listing such as Nasdaq and expects to announce effectiveness in early 2026. Filing materials are available on EDGAR.
Adia Med (OTCQB: ADIA) announced a media partnership with 3X physician and talk-show host Dr. Asa Andrew and The Dr. Asa Network on December 1, 2025. The agreement names Dr. Asa as an official media partner, spokesperson, and content creator for Adia Med to produce exclusive digital, social, radio, TV, podcast, and docu-series content focused on stem cell therapies and longevity medicine. Leadership states the partnership aims to increase awareness, education, and access to Adia Med's regenerative treatments and to support clinic licensing and strategic partnerships.